Years of life lost and healthy life-years lost from diabetes and cardiovascular disease in overweight and obese people: a modelling study. Lancet Diabetes Endocrinol. 2015 Feb;3(2):114-22. doi: 10.1016/S2213-8587(14)70229-3. Epub 2014 Dec 5.
Increasing the effectiveness of the Diabetes Prevention Program through if-then plans: study protocol for the randomized controlled trial of the McGill CHIP Healthy Weight Program. BMC Public Health. 2014 May 18;14:470. doi: 10.1186/1471-2458-14-470.
The association between sleep disturbance, depressive symptoms, and health-related quality of life among cardiac rehabilitation participants. J Cardiopulm Rehabil Prev. 2014 May-Jun;34(3):188-94. doi: 10.1097/HCR.0000000000000054.
Impact of a pedometer program on nurses working in a health-promoting hospital. Health Care Manag (Frederick). 2014 Apr-Jun;33(2):172-80. doi: 10.1097/HCM.0000000000000010.
Determinants and benefits of physical activity maintenance in hospital employees. Health Care Manag (Frederick). 2014 Jan-Mar;33(1):82-90. doi: 10.1097/HCM.0b013e3182a9d682.
The impact of cardiovascular risk-factor profiles on blood pressure control rates in adults from Canada and the United States. Can J Cardiol. 2013 May;29(5):598-605. doi: 10.1016/j.cjca.2012.12.004. Epub 2013 Mar 1.
The MyHealthCheckup study: Training graduate students to implement cardiovascular risk screening programs in community pharmacies. Can Pharm J (Ott). 2012 Nov;145(6):268-75. doi: 10.3821/145.6.cpj268.
Effect of exercise in reducing breast and chest-wall pain in patients with breast cancer: a pilot study. Curr Oncol. 2012 Jun;19(3):e129-35. doi: 10.3747/co.19.905.
The challenges and benefits of cardiovascular risk assessment in clinical practice. Can J Cardiol. 2011 Jul-Aug;27(4):481-7. doi: 10.1016/j.cjca.2011.04.008. Review. English, French.
Estimating the Benefits of Patient and Physician Adherence to Cardiovascular Prevention Guidelines: The MyHealthCheckUp Survey. Can J Cardiol. 2011 Mar-Apr;27(2): 159-66.
The 2010 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I - blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 2010;26(5):1.
2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol. 2009 Oct;25(10):567-79.
Evaluating the Incremental Benefits of Raising High Density Lipoprotein Cholesterol during Lipid Therapy after Adjustment for the Reductions in Other Blood Lipid Levels. Arch Intern Med. 2009 Oct 26;169(19):1775-80.
Discussing Coronary Risk with Patients to Improve Blood Pressure Treatment: Secondary results from the CHECK-UP Study. J Gen Intern Med. 2009;24:33-39.
Food for thought: weight change during diet and exercise interventions among overweight adults with type 2 diabetes. Canadian Journal of Diabetes. 2008;32(4):255-259.
Preventing Cardiovascular Disease Among Canadians: Is the treatment of Hypertension or Dyslipidemia Cost-Effective? Can J Cardiol 2008;24:891-8.
Determining the Cost-Effectiveness of Preventing Cardiovascular Disease: Are Estimates Calculated Over the Duration of a Clinical Trial Adequate? Can J Cardiol 2008;24(4):261-266.
Estimating the Cost-Effectiveness of Ramipril use for Specific Clinical Indications: Comparing the Outcomes of Four Clinical Trials with a Common Economic Model. Am J Cardiovasc Drugs. 2007;7(6):441-448.
Preventing cardiovascular disease among Canadians: What are the potential benefits of treating hypertension or dyslipidemia? Can J Cardiol 2007;23: 467-473.
Patient Knowledge of Coronary Risk Profile Improves the Effectiveness of Dyslipidemia Therapy: The CHECK-UP Study: A Randomized Controlled Trial. Arch Intern Med. 2007:26;167:2296-303.
Barriers and remaining questions on assessment of absolute cardiovascular risk as a starting point for interventions to reduce cardiovascular risk. J Hypertens. 2006;24(9): 1683-5.
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II - Therapy. Can J Cardiol. 2006;22(7):583-93.
The 2006 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I--Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol. 2006;22(7):573-81.
The role of global risk assessment in hypertension therapy. Can J Cardiol. 2006;22(7):606-613.
PROVE-IT Proves that lower is better: A contrary view. Can J Cardiol. 2006 Feb;22 Suppl B:95B-6B.
Evaluation of a decision aid and a personal risk profile in community pharmacy for patients considering options to improve cardiovascular health: The OPTIONS pilot study International. Journal of Pharmacy Practice. 2006;14(1):51-62.
Do the benefits of finasteride outweigh the risks in the Prostate Cancer Prevention Trial (PCPT)? J Urol. 2006;175:934-938.
Impact of modified glucose target and exercise interventions on vascular risk factors. Diabetes Research and Clinical Practice 2006;72(1):53-60.
The prevalence of erectile dysfunction in the primary care setting: The importance of risk factors for diabetes and vascular disease. Arch Intern Med. 2006;166:213-219.
Sulfonylurea use associated with reduction in blood glucose levels during exercise stress testing. J Cardiopulm Rehabil 2005;25(4):222-225.
Cost-effectiveness of lipid-lowering treatment according to lipid level. Can J Cardiol 2005;21:681-687.
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part II : Therapy. Can J Cardiol 2005;21:657-672.
The 2005 Canadian Hypertension Education Program recommendations for the management of hypertension: Part I : Blood pressure measurement, diagnosis and assessment of risk. Can J Cardiol 2005;21:645-656.
A randomized clinical trial of an individualized home-based exercise programme for women with fibromyalgia. Rheumatology 2005;44:1422–1427.
Dyslipidemia associated with highly active antiretroviral therapy (HAART): The impact on cardiovascular risk and life expectancy. Am J Cardiol 2005;95:586-591.
Treating osteoarthritis with COX-2 specific inhibitors: What are the benefits of avoiding blood pressure destabilization among hypertensive Americans? Hypertension 2005;45:92-97.
Development and preliminary testing of a patient decision aid to assist pharmaceutical care in the prevention of cardiovascular disease. Pharmacotherapy 2004;24:909-922.
Health-related quality of life in cardiac patients with dyslipidemia and hypertension. Qual Life Res 2004;13:793-804.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Macrovascular complications, dyslipidemia and hypertension. Canadian Diabetes Association 2003 Clinical Practice Guidelines for the Prevention and Management of Diabetes in Canada. Can J Diabetes 2003;27(suppl 2):S58-S65.
Evaluating the benefits of treating dyslipidemia among Americans: The importance of diabetes as a risk factor. Am J Med 2003;115:122-128
Application of the 1998 Canadian cholesterol guidelines to a military population: Health benefits and cost-effectiveness of improved cholesterol management. Can J Cardiol 2003;19:790-796.
Improving the prediction of cardiovascular risk: Interaction between LDL and HDL cholesterol. Epidemiol 2003;14;315-320.
The importance of indirect costs in primary cardiovascular disease prevention: Can we save lives and money with statins? Arch Intern Med 2003;163:333-339.
Comparing the benefits of diet and exercise in the treatment of dyslipidemia. Prev Med 2002;35:16-24.
The 2001 Canadian recommendations for the management of hypertension: Part two – Therapy. Can J Cardiol 2002;18:625-641.
The 2001 Canadian recommendations for the management of hypertension: Part one – Assessment for diagnosis, cardiovascular risk, causes and lifestyle modification. Can J Cardiol 2002;18:604-624.
Health-related quality of life with coronary heart disease prevention and treatment. J Clin Epidemiol 2001;54:1011-1018.
How cost-effective is the treatment of dyslipidemia in patients with diabetes but without cardiovascular disease? Diabetes Care 2001;24:45-50.
Cost-effectiveness of treating hyperlipidemia in the presence of diabetes: Who should be treated? Circulation 2000;102:722-727.
The Cost-Effectiveness of Exercise Training for the Primary and Secondary Prevention of Cardiovascular Disease. Journal of Cardiopulmonary Rehabilitation 2000;20:147-155.
Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines. Can Med Assoc J 2000;163(10):1263-1269.
When should hypertension be treated? The different perspectives of Canadian family physicians and patients. Can Med Assoc J 2000;163(4):403-408.
Role of WHO MONICA Project in unravelling of the cardiovascular puzzle [commentary]. The Lancet 2000;355:668-669.
The economic burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:987-92.
The clinical burden of prostate cancer in Canada: forecasts from the Montreal Prostate Cancer Model. Can Med Assoc J 2000;162:977-83.
Estrogen replacement among women with cardiovascular disease: Why don’t physicians and patients follow the guidelines? [Invited Editorial] Can Med Assoc J 1999;161:42-43.
Comparing the psychometric properties of preference-based and nonpreference-based health-related quality of life in coronary heart disease. Qual Life Res 1999;8:399-409.
Impact of treating hyperlipidemia or hypertension to reduce the risk of death from coronary artery disease. Can Med Assoc J 1999;160:1449-1455.
Conventional and chained standard gamble in the assessment of coronary heart disease prevention and treatment. Med Decis Making 1999;19:149-156.
The cost-effectiveness of HMG-CoA reductase inhibitors in the secondary prevention of cardiovascular disease: Forecasting the incremental benefits of preventing coronary and cerebrovascular events. Arch Intern Med 1999;159:593-600.
Gambling with cardiovascular risk: Picking the winners and the losers. [Invited Editorial] The Lancet 1999;353:254-255.
Prostate cancer: 12. The economic burden. Can Med Assoc J 1999;160:685-690.
Identifying those at low risk for significant hyperlipidemia. A validated clinical index. J Clin Epidemiol 1999;52:49-55.
Can Computerized Risk Profiles Help Patients Improve Their Coronary Risk? The Results of The Coronary Health Assessment Study (CHAS). Preventive Medicine 27, 730–737 (1998).
Estimating the benefits of modifying risk factors of cardiovascular disease: A comparison of primary vs secondary prevention. Arch Intern Med 1998;158:655-662.
Treating hyperlipidemia for the primary prevention of coronary disease: Are higher doses of lovastatin cost-effective? Arch Intern Med 1998;158:375-381.
Who Needs an Exercise Stress Test? Evaluating the New American College of Sports Medicine Risk Stratification Guidelines. Journal of Cardiopulmonary Rehabilitation, 1997; 17:253-260.
Flexible modeling of the effects of serum cholesterol on coronary heart disease mortality. Am J Epidemiol 1997;145:714-729.
A head to head comparison of the cost-effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia. Cardiovasc Drugs Ther 1996;10:787-794.
Cost-effectiveness of assessment and management of risk factors. Bethesda Conference #27. J Am Coll Cardiol 1996;27(5):964-1047.
The relationship between dietary intake and coronary heart disease mortality: The Lipid Research Clinics Prevalence Follow-up Study. J Clin Epidemiol 1996;49(2):211-216.
Identifying adults at increased risk of coronary disease: How well do the current cholesterol guidelines work? JAMA 1995;274:801-806.
Do doctors accurately assess coronary risk in their patients? Preliminary results of the Coronary Health Assessment Study (CHAS). BMJ 1995;310:975-978.
The cost-effectiveness of HMG-CoA reductase inhibitors to prevent coronary heart disease: Estimating the benefits of increasing HDL-C. JAMA 1995;273(13):1032-1038.
Life expectancy following dietary modification or smoking cessation: Estimating the benefits of a prudent lifestyle. Arch Intern Med 1994;154:1697-1704.
Serum lipid screening to identify high risk individuals for coronary death: The results of the Lipid Research Clinics Prevalence Cohort. Arch Intern Med 1994;154(6):679-684.
Economic impact of HIV infection and coronary heart disease in immigrants to Canada. Can Med Assoc J 1992;147(8):1163-1172.
The benefits of treating hyperlipidemia to prevent coronary heart disease: Estimating changes in life expectancy and morbidity. JAMA 1992;267(6):816-822.
Screening for hypercholesterolemia among Canadians: How much will it cost? Can Med Assoc J 1991;144(2):161-168.
HIV antibody screening among immigrants: A cost/benefit analysis. Can Med Assoc J 1990;143(2):101-107.